Ludivine Kouton

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 587 citations · Full text

Medicine, Generalised Myasthenia Gravis

Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP

Andrea Cortese, Raffaella Lombardi, Chiara Briani et al. · Neurology Neuroimmunology & Neuroinflammation · 2019 · 170 citations · Full text

Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera

Émilien Delmont, Alexandre Brodovitch, Ludivine Kouton et al. · Journal of Neurology · 2020 · 103 citations · Full text

Rheumatology, Medical Diagnostics, Allergy +10

Electrophysiological features of chronic inflammatory demyelinating polyradiculoneuropathy associated with IgG4 antibodies targeting neurofascin 155 or contactin 1 glycoproteins

Ludivine Kouton, José Boucraut, Jérôme Devaux et al. · Clinical Neurophysiology · 2020 · 57 citations · Full text

Igg4 Antibodies, Autoimmune Disease, Chronic Inflammatory +13

Motor unit number index as an individual biomarker: Reference limits of intra-individual variability over time in healthy subjects

Émilien Delmont, François‐Charles Wang, Jean‐Pascal Lefaucheur et al. · Clinical Neurophysiology · 2020 · 18 citations · Full text

Individual Biomarker, Kinesiology, Healthy Subjects +9